Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alpha Cognition Inc
(OP:
ACOGF
)
0.3900
-0.0493 (-11.22%)
Streaming Delayed Price
Updated: 3:42 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alpha Cognition Inc
< Previous
1
2
Next >
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease
August 19, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth
August 13, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease
July 29, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
March 08, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
March 05, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Alpha Cognition to Present at the Life Science Investor Forum March 7th
March 01, 2024
Company invites individual and institutional investors, as well as advisors and analysts, to attend in person or online at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease
February 22, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Provides Business Update
February 12, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment
January 19, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
December 22, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
December 07, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering
December 04, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
October 16, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering
August 31, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Life Science Investor Forum: Presentations Now Available for Online Viewing
June 23, 2023
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Science Investor Forum Agenda Announced for June 22nd
June 20, 2023
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Alpha Cognition Launches $6.5 Million Private Placement
May 30, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
March 08, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Provides Private Placement Update
March 06, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update
November 28, 2022
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update
August 25, 2022
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease
August 22, 2022
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease
June 22, 2022
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Successful Defense of European Patent Covering ALPHA-0602
June 15, 2022
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Positive Data from Pre-Clinical Studies and Discovery of GEM Combinations with Potential for Neurodegenerative Disease Treatment
June 13, 2022
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Grant of Stock Options
May 31, 2022
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces First Quarter 2022 Results and Company Update
May 31, 2022
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Fourth Quarter and Full Year 2021 Results and Company Update
April 28, 2022
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Change of CFO, Grant of Stock Options and Addition to the Board of Directors
April 12, 2022
From
Alpha Cognition Inc.
Via
Business Wire
Alpha Cognition Announces Positive Data from Pre-Clinical Studies of ALPHA-0602 (Progranulin) for Amyotrophic Lateral Sclerosis (ALS)
March 29, 2022
From
Alpha Cognition Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.